Neurologix Reports Second Quarter 2010 Financial Results

FORT LEE, N.J., Aug. 12 /PRNewswire-FirstCall/ — Neurologix, Inc. (OTCBB: NRGX) (the “Company”), a biotechnology company developing innovative gene therapies for the brain and central nervous system (“CNS”), today reported its financial results for the three and six months ended June 30, 2010. “We are extremely pleased with the continued success of NLX-P101, our Parkinson’s disease gene therapy …